Kortikoid-Ratiopharm (Triamcinolone Acetonide)

Triamcinolone acetonide penetrates the skin and binds to intracellular glucocorticoid receptors. This complex alters gene transcription, increasing anti‑inflammatory proteins while suppressing pro‑inflammatory cytokines, prostaglandins and other mediators. The result is decreased inflammation, reduced immune cell activity and relief of symptoms.

The appropriate dose and duration are determined by the prescribing healthcare professional based on the specific condition, severity, patient age and the area of skin to be treated. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety data for triamcinolone acetonide in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Kortikoid‑Ratiopharm (triamcinolone acetonide) is a mid‑potency glucocorticoid, offering a balance between efficacy and risk of skin atrophy compared with higher‑potency agents such as betamethasone dipropionate. It provides strong anti‑inflammatory action while generally causing fewer systemic effects when used as directed.

Store the product at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed when not in use and keep it out of reach of children. Do not freeze or expose to extreme heat.

Apply a thin layer of the cream or ointment to the affected skin area, usually 1–2 times daily, unless otherwise directed by a clinician. Wash hands before and after application, avoid contact with eyes, and do not cover the treated area with occlusive dressings unless instructed.

Serious risks include skin atrophy or thinning, development of telangiectasia, hypopigmentation, and, rarely, systemic glucocorticoid effects such as adrenal suppression when large areas are treated or occlusion is used. Secondary infections of the skin may also occur and require medical attention.

Patients with known hypersensitivity to triamcinolone acetonide or any excipients in the formulation should avoid use. It is also contraindicated on skin infected with bacterial, fungal or viral agents unless combined with appropriate antimicrobial therapy, and should be used with caution in patients with uncontrolled diabetes, severe skin atrophy or systemic steroid therapy.